Emesis occurs occasionally in dogs, and frequently in cats, soon after the administration of xylazine, but before clinical sedation is evident. When observed, emesis usually occurs only a single time, after which there is no further emetic effect. The use of anti-emetics may delay this phenomenon. The occurrence of emesis may be considered a desirable effect when xylazine is administered as a pre-anesthetic to general anesthesia. Xylazine used at the recommended dosage levels may occasionally cause slight muscle tremors, bradycardia with partial A-V heart block and a reduced respiratory rate. Should excessive respiratory depression or bradycardia occur following the use of AnaSed^® (xylazine), administer yohimbine to rapidly reverse the xylazine-induced effects.

Gaseous extension of the stomach may occur in dogs treated with xylazine making radiographic interpretation more difficult.

Movement in response to sharp auditory stimuli may be observed.

Increased urination may occur in cats following the use of xylazine.

Precautions

Clinical results with xylazine have not revealed any detrimental effects when the compound is administered to pregnant dogs or cats. However, until more definitive studies are completed, xylazine is not recommended for use in these animals.

Careful consideration should be given before administering to dogs or cats with significantly depressed respiration, severe pathologic heart disease, advanced liver or kidney disease, severe endotoxic or traumatic shock and stress conditions such as extreme heat, cold, or fatigue.

Analgesic effect is variable, and depth should be carefully assayed prior to surgical/clinical procedures. In spite of sedation, the practitioner and handlers should proceed with caution since defense reactions may not be diminished.

Do not use xylazine in conjunction with tranquilizers.

Since an additive effect results from the use of